Because BCL-2 inhibitors (particularly venetoclax) have shown encouraging responses in MDS, future prospective trials could assess whether baseline or on-treatment BCL-2 immunostaining (or allied techniques such as flow cytometry or transcriptomics) can predict therapeutic success. This evidence concerns the gene BCL2 and myelodysplastic syndrome.